{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:05:00Z","timestamp":1747170300366,"version":"3.40.5"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":116,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.rmcr.2024.102029","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T06:33:29Z","timestamp":1714199609000},"page":"102029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis"],"prefix":"10.1016","volume":"49","author":[{"given":"Taisuke","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5263-3238","authenticated-orcid":false,"given":"Kazuo","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rmcr.2024.102029_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jjco\/hyy179","article-title":"Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset","volume":"49","author":"Ohe","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.rmcr.2024.102029_bib2","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/cas.12550","article-title":"Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer","volume":"105","author":"Gemma","year":"2014","journal-title":"Cancer Sci."},{"issue":"16","key":"10.1016\/j.rmcr.2024.102029_bib3","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","article-title":"Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib","volume":"24","author":"Ando","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.rmcr.2024.102029_bib4","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1111\/cas.14120","article-title":"Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: a pooled subgroup analysis","volume":"110","author":"Hirashima","year":"2019","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.rmcr.2024.102029_bib5","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/cas.13623","article-title":"Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial","volume":"109","author":"Akamatsu","year":"2018","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.rmcr.2024.102029_bib6","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.chest.2022.05.035","article-title":"Drug-related pneumonitis induced by osimertinib as first-line treatment for epidermal growth factor receptor mutation-positive non-small cell lung cancer: a real-world setting","volume":"162","author":"Sato","year":"2022","journal-title":"Chest"},{"year":"2018","series-title":"The JRS Guidelines for the Management of Drug-Induced Lung Disease","author":"Society","key":"10.1016\/j.rmcr.2024.102029_bib7"},{"issue":"2","key":"10.1016\/j.rmcr.2024.102029_bib8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10637-020-01005-1","article-title":"Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma","volume":"39","author":"Kodama","year":"2021","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.rmcr.2024.102029_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejca.2022.10.029","article-title":"Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: a multicentre retrospective cohort study","volume":"179","author":"Imaji","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.rmcr.2024.102029_bib10","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/j.jtho.2016.08.144","article-title":"Transient asymptomatic pulmonary opacities occurring during osimertinib treatment","volume":"11","author":"Noonan","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.rmcr.2024.102029_bib11","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jtho.2018.04.038","article-title":"Transient asymptomatic pulmonary opacities during osimertinib treatment and its clinical implication","volume":"13","author":"Lee","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.rmcr.2024.102029_bib12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00280-017-3261-5","article-title":"Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease","volume":"79","author":"Kashiwabara","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"10.1016\/j.rmcr.2024.102029_bib13","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmcr.2024.102029_bib14","first-page":"6","volume":"vol. 59","author":"Matsuo T","year":"2019"},{"issue":"5","key":"10.1016\/j.rmcr.2024.102029_bib15","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jtho.2017.01.027","article-title":"Successful osimertinib rechallenge in a patient with T790M-mutant non-small cell lung cancer after osimertinib-induced interstitial lung disease","volume":"12","author":"Miyauchi","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.rmcr.2024.102029_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2169\/internalmedicine.8947-17","article-title":"Successful osimertinib rechallenge with steroid therapy after osimertinib-induced interstitial lung disease","volume":"57","author":"Kiriu","year":"2018","journal-title":"Intern. Med."},{"issue":"1","key":"10.1016\/j.rmcr.2024.102029_bib17","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.cllc.2017.06.017","article-title":"Retreatment with osimertinib following pneumonitis","volume":"19","author":"Nagasaka","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.rmcr.2024.102029_bib18","article-title":"Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: a case report","volume":"33","author":"Sato","year":"2021","journal-title":"Respir Med Case Rep"},{"issue":"24","key":"10.1016\/j.rmcr.2024.102029_bib19","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.2169\/internalmedicine.5048-20","article-title":"Usefulness of rapid desensitization therapy for severe rash caused by molecularly targeted drugs used in the treatment of non-small-cell lung cancer","volume":"59","author":"Nagase","year":"2020","journal-title":"Intern. Med."},{"issue":"7","key":"10.1016\/j.rmcr.2024.102029_bib20","first-page":"6","article-title":"A case of successful desensitization therapy for lsoniazid-induced pneumonitis","volume":"42","author":"Nishizawa Y","year":"2004","journal-title":"Nihon Kokyuki Gakkai Zasshi"}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007124000522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007124000522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T11:47:53Z","timestamp":1724154473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007124000522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":20,"alternative-id":["S2213007124000522"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2024.102029","relation":{},"ISSN":["2213-0071"],"issn-type":[{"type":"print","value":"2213-0071"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2024.102029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102029"}}